Tag Archives: valeant pharmaceuticals

June, 2018

  • 18 June

    FDA Fails to Approve Valeant’s Plaque Psoriasis Treatment

    LAVAL, Quebec, June 18, 2018 /PRNewswire/ — Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) …

April, 2017

November, 2016

  • 2 November

    Valeant Comments on Potential Sale of its Gastroenterology Business Unit

    LAVAL, Quebec, Nov. 1, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) today issued the following statement regarding comments attributed to anonymous sources in a press report regarding its Gastroenterology business unit: “In accordance with its duties to shareholders and other stakeholders, management evaluates any …

July, 2016

  • 20 July

    FDA Panel Recommends Approval of Valeant’s Psoriasis Drug

    LAVAL, Quebec, July 19, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) has voted by a margin of 18 to 0 for the approval of brodalumab injection, 210 …

March, 2015

  • 16 March

    Valeant Raises its Offer to Acquire Salix

    After Endo International offered a rival bid, Valeant Pharmaceuticals International announced that it has raised its offer for gastrointestinal drugmaker Salix Pharmaceuticals. The companies announced that they have entered into an amendment to their agreement and plan merger. Valeant has increased its offer price to acquire all the outstanding common …

  • 11 March

    Endo Threatens Valeant’s Deal with Competing Bid for Salix Pharmaceuticals

    Today, Endo International plc confirmed that it has made a takeover bid for Salix Pharmaceuticals Ltd., looking to interrupt Valeant’s plans to acquire the gastrointestinal drugmaker. Endo said that it has submitted a proposal to the Board of Directors of Salix to acquire all of the outstanding shares of common …

February, 2015

  • 23 February

    Valeant to Buy Salix Pharmaceuticals for $10.1 Billion

    Valeant Pharmaceuticals International Inc. announced that it is buying Salix Pharmaceuticals Ltd. for $10.1 billion. Valeant is paying $158 a share for Salix, gaining a portfolio of gastrointestinal (GI) drugs and a strong near-term pipeline of innovative, new assets. The deal values Salix at about $14.5 billion including net debt …